Meeting
2018 Genitourinary Cancers Symposium
Evaluating changes in circulating tumor cell count in prostate cancer patients during androgen deprivation plus chemotherapy by using AxonDx enumeration device.
Authors
Reynolds Brobey
UT Health Science Center, Houston, TX
Reynolds Brobey , Robert J. Amato , Jeff Smith , Mehdi Dehghani , Kent Murphy , Yue Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 266)
DOI
10.1200/JCO.2018.36.6_suppl.266
Abstract #
266
Poster Bd #
M20
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Biological significance of novel populations of prostate cancer circulating tumor cells (CTC).
First Author: Ian D. Davis
Poster
2014 Genitourinary Cancers Symposium
Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC).
First Author: Himisha Beltran
Poster
2023 ASCO Genitourinary Cancers Symposium
Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer.
First Author: Elias Chandran
Poster
2022 ASCO Genitourinary Cancers Symposium
A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naïve prostate cancer (mHNPC): ZZFIRST.
First Author: Joaquin Mateo